Bruker Also Announces First MPI Customer Installation, new PCI Center in
Singapore
SEOUL, South Korea--(BUSINESS WIRE)-- At the 2014
World Molecular Imaging Congress(WMIC,www.wmis.org),
Brukertoday introducesnew products for improved performance and customer experience in preclinical imaging, and announces related achievements:
NEW PRODUCT:SkyScan™ 1278, the world’s fastest, low-dose, high-resolution micro-CT:With the launch of the next-generationSkyScan 1278micro-CT system forin vivoX-ray computed tomography,
Brukeris addressing the latest needs of preclinical imaging scientists striving to reduce the radiation dose used in animal studies, while maintaining highest image quality. As part of the development,
Brukerhas created a new micro-CT spatial beam shaper, which reduces the absorbed dose by up to five times, while maintaining high quality image output.
TheSkyScan 1278has a highly sensitive flat-panel detector that is able to deliver images of mouse heart and lung activities even without a contrast agent. Such images allow the user to explore cardiac and respiratory function, while reducing animal stress and the cost of the study. A full-body animal scan can take 8 seconds or less, reducing run times and increasing the speed of data collection.
FIRST CUSTOMER INSTALLATION:
Brukerannounces the first customer installation of itsMPI PreClinical, a preclinical Magnetic Particle Imaging (MPI) scanner, at the University Medical Center Hamburg-Eppendorf (UKE),
Germany. Significantly, this marks the first time that MPI technology has been delivered in a commercial system. Preclinical MPI is an entirely new technology forin vivoimaging of small animals used in translational research.
The newMPI PreClinical于2013年宣布,是力量的结果”s collaboration with
Royal Philips(NYSE: PHG, AEX: PHIA). It combines Bruker’s leadership in preclinical imaging with Philips’ strength in medical imaging. MPI was invented by scientists at Philips and uses the detection of magnetic iron-oxide nanoparticles injected into the bloodstream to produce three-dimensional images at millisecond intervals, providing the potential for real-time 3D imagingin vivo. MPI’s high time-resolution allows researchers to investigate a range of dynamic issues, e.g. in cardiovascular research, which cannot be studied using other techniques.
NEW PRODUCT: BioSpec 21T Ultra-high Field MRI with CryoProbe
Brukerintroduces theBioSpec®210/11, a new 21 Tesla ultra-high field MRI withCryoProbe™ for small animal Magnetic Resonance Imaging (MRI). Asin vivoinvestigation shifts from organ and tissue imaging to cellular and molecular research, a significant boost in sensitivity and resolution is required. With the unique 21T MRI,
Brukercustomers can set new performance benchmarks and gain new insights in preclinical research.
TheBioSpec 210/11is based on Bruker’s proven 21 Tesla 11 cmUSR™ magnet that is already successfully used in FT-mass spectrometry.UltraShield™magnet technology reduces magnetic stray fields, while Bruker’s active refrigeration technology virtually eliminates cryogen refills, reducing down-time and user maintenance efforts.
NEW PCI CENTER:
Brukerhas enjoyed a long-term partnership with the
Singapore Bioimaging Consortium(SBIC), and the new SBIC-Bruker Preclinical Imaging (PCI) Center in
Singaporeconsolidates bio-imaging capabilities to promote innovation in biological research. The PCI facility, due to open in
October 2014,将提供先进的示范,培训一个d applications support for Bruker’s industry-leading preclinical portfolio and multi-modal imaging platforms. By combining PCI technologies and modalities, the center will play a key role in promoting the application of complementary imaging information.
Wulf I. Jung, Ph.D., President of Bruker’s Preclinical Imaging division, stated: “At WMIC 2014, we continue ourInnovation with Integrityto enable the success of our customers. With differentiated, high performance products we enable novel preclinical imaging research and gain access to new markets, while maintaining our excellent reputation in the scientific research community.”
About
Bruker Corporation
Bruker(NASDAQ: BRKR) is a leading provider of high-performance scientific instruments and solutions for molecular and materials research, as well as forin vitrodiagnostics, industrial and applied analysis.
For more information on Bruker’s Preclinical Imaging division, please visitwww.energie2point0.com/preclinicalimaging.
Photos/Multimedia Gallery Available:http://www.businesswire.com/multimedia/home/20140917005787/en/
Source:
Bruker Corporation